Pharmaceuticals, Biotechnology and Life Sciences
“The results of this Keytruda plus Lenvima study are a welcome development in the treatment of women with advanced endometrial cancer, a patient group with an unmet medical need,” said Dr. Vicky Makker, principal investigator and medical oncologist, Memorial Sloan Kettering Cancer Center.
Italian biopharmaceutical specialist for nervous diseases solutions, Newron Pharmaceuticals, and it’s partners Meiji Seika Pharma together with Eisai, got approval to produce and sell Equifina tablets in Japan.
Keytruda/lenvima combination treatment has been approved for certain patients with advanced endometrial carcinoma which isn’t Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR)
BOSTON–(BUSINESS WIRE)–Cerveau Technologies, Inc. today announced a research collaboration agreement with Eisai Inc., which will enable Eisai to use Cerveau’s…
Eisai Co said Friday thata global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer’s disease has been initiated.
ProMIS Neurosciencesissued a pres release Friday, raising urgency to selectively target the toxic oligomer with exacting precision as part of the global effort to develop disease-modifying therapies for Alzheimer’s disease (AD), upon Biogen’s and Eisai’s dropping two alte-stage clinical trials of aducanumab.